If you are researching CJC-1295 in Canada, you may be looking for information about growth hormone signalling, recovery, body composition or healthy aging. CJC-1295 is an experimental growth hormone-releasing hormone analogue. Interest is high, but its regulatory status and level of human evidence matter.
Peptides Canada helps Canadians understand the research and connect with qualified Canadian healthcare providers.
Find a Canadian Peptide Provider
What Is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, often shortened to GHRH. It was developed to extend the activity of GHRH and increase growth hormone and IGF-1 signalling. You may see references to CJC-1295 with DAC and versions marketed without DAC. These are not interchangeable terms, and online marketing often blurs the difference.
CJC-1295 is frequently discussed alongside ipamorelin, a growth hormone secretagogue that works through a different receptor pathway.
Why Are Canadians Interested in CJC-1295?
Search interest usually centres on recovery, sleep, muscle development, fat metabolism and age-related changes in growth hormone. These are commercially popular claims, but the evidence is much narrower than the marketing suggests.
Human pharmacology studies have shown that CJC-1295 can affect growth hormone and IGF-1 levels. That does not establish that it improves athletic performance, body composition, injury recovery or healthy aging in the general population.
CJC-1295 Benefits Being Researched
Growth Hormone and IGF-1
The clearest research interest is its effect on the GH-IGF-1 axis. Researchers have studied whether longer-acting GHRH analogues can increase hormone signalling while preserving some physiological pulsatility.
Body Composition and Recovery
CJC-1295 is promoted online for muscle gain, fat loss and recovery. Current reviews note that clinical evidence for performance and physique uses remains limited. Claims should therefore be separated from proven treatment outcomes.
Healthy Aging
Age-related changes in growth hormone have made GHRH analogues interesting to longevity clinics. Increasing a hormone marker, however, is not the same as proving longer life, better healthspan or improved function.
CJC-1295 vs Ipamorelin
CJC-1295 and ipamorelin are often marketed together because they influence growth hormone through different pathways. CJC-1295 acts as a GHRH analogue, while ipamorelin is a growth hormone secretagogue. Combination protocols promoted online should not be treated as established clinical standards.
Read our Ipamorelin Canada guide for the evidence and Canadian status of ipamorelin.
Human Research on CJC-1295
Human pharmacology research has examined CJC-1295 and its effects on growth hormone and IGF-1. Evidence for many of the broader benefits promoted online remains limited.
Is CJC-1295 Legal in Canada?
Health Canada has specifically identified CJC-1295 among unauthorized injectable peptide drugs encountered in Canada. Injectable peptides are regulated as prescription drugs. A product labelled “research use only” does not become legal for human use simply because of that label.
Canadians should verify the exact product and authorization status rather than assuming that a website shipping from Canada is selling an authorized drug.
Can You Buy CJC-1295 in Canada?
Websites advertise CJC-1295 for sale in Canada, but online availability does not establish authorization, purity, sterility or legal sale for human use. For prescription drugs, Canadians should look for a valid Drug Identification Number when applicable and use licensed pharmacies.
If you are interested in growth hormone-related treatment, speak with a licensed healthcare provider who can assess your goals and discuss authorized options.
Find a CJC-1295 or Peptide Provider in Canada
Instead of choosing a peptide seller based on marketing claims, start with a qualified Canadian provider. Peptides Canada is building a directory to help Canadians find clinics and professionals who can discuss peptide therapy, metabolic health and related treatment options.
CJC-1295 Safety and Risks
Potential concerns with compounds that alter the GH-IGF-1 axis include fluid retention, changes in blood sugar, endocrine effects, joint or muscle symptoms and injection-site reactions. Long-term safety for unapproved CJC-1295 use has not been established.
Unauthorized injectable products add separate risks involving sterility, incorrect strength, contamination and inaccurate ingredients.